B3 · BRL
VVEO3
CM Hospitalar SA
- Day's range
- R$0.77 – R$0.80
- Day's volume
- R$75.4k
- 52-week range
- R$0.56 – R$1.86
Follow VVEO3 on Fuolio
See how VVEO3 weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountVVEO3 in numbers
- Market cap
- R$251.8m
- P/E
- 4.37
- P/B
- 0.14
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- 6.16
VVEO3 trades at 4.37 times its earnings of the last 12 months.
VVEO3 price history
VVEO3 risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | -45.83% | -94.62% | -95.82% |
| Volatility (annualised) | 61.46% | 62.00% | 54.37% |
| Largest drawdown | -60.00% | -95.31% | -96.70% |
| Positive months | 6/12 | 13/36 | 23/60 |
How much did investing in VVEO3 return?
R$1,000.00 invested on 01/10/2021 would be worth R$41.27 today.
- Value today in VVEO3
- R$41.27
- Return over the period
- -95.87%
- Return per year
- -47.15%
- In the Ibovespa
- R$1,808.65
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
VVEO3 fundamentals
Valuation
- P/E4.37
- P/B0.14
- EV/EBITDA6.42
- EV/EBIT10.04
- EV/Revenue0.53
- P/EBIT0.40
- P/S0.02
- P/OCF0.94
- P/FCF3.26
- Earnings yield9.96%
- PEG ratio0.04
- Earnings per shareR$0.18
- Book value per shareR$5.65
Debt
- Net debtR$6bn
- Net debt/EBITDA6.16
- Net debt/Equity3.29
- Debt/Equity3.53
- Current ratio1.72
- Quick ratio1.03
- Cash ratio0.17
Efficiency
- Gross margin15.31%
- EBITDA margin8.31%
- Operating margin5.31%
- Net margin0.49%
- Asset turnover1.34
Profitability
- ROE3.12%
- ROA0.65%
- ROIC7.96%
- Payout0.00%
Growth
- Revenue CAGR (5 years)—
- Earnings CAGR (5 years)—
- Revenue growth (year)-0.14%
- Earnings growth (year)101.29%
- Revenue growth (quarter)2.06%
- Earnings growth (quarter)103.89%
What is VVEO3's fair price?
Two classic value formulas, with today's numbers. The current price is R$0.77.
- Graham's fair price
- R$4.73
- 514.36% above the price
√(22.50 × R$0.18 × R$5.65)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- R$3.41
- 343.42% above the price
R$0.20 (4-year average) ÷ 6%
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
VVEO3 indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| P/E | 25.13 | -0.47 | 12.51 | 17.71 | 13.62 | — |
| P/B | 0.24 | 0.34 | 1.37 | 2.02 | 2.50 | — |
| EV/EBITDA | 7.33 | — | 10.62 | 16.51 | 11.67 | — |
| Dividend yield | 0.00% | 6.66% | 1.98% | 2.53% | — | — |
| Earnings per share | R$0.06 | -R$4.38 | R$1.11 | R$0.91 | R$1.38 | R$0.38 |
| Book value per share | R$6.00 | R$5.97 | R$10.19 | R$7.97 | R$7.52 | R$3.72 |
| ROE | 0.94% | -73.47% | 10.94% | 11.39% | 18.37% | 10.14% |
| ROIC | 2.72% | -9.47% | 7.65% | 7.79% | 13.00% | 7.47% |
| Gross margin | 14.43% | 11.27% | 15.65% | 15.97% | 17.65% | 14.47% |
| EBITDA margin | 7.45% | -4.76% | 8.09% | 6.17% | 9.50% | 6.33% |
| Net margin | 0.16% | -12.22% | 3.25% | 2.97% | 6.35% | 2.76% |
| Net debt/EBITDA | 6.80 | — | 5.60 | 7.98 | 2.56 | 1.77 |
VVEO3 financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | R$11.6bn | R$11.6bn | R$11.1bn | R$8.7bn | R$6.2bn | R$4.4bn |
| Cost of sales | -R$9.9bn | -R$10.3bn | -R$9.3bn | -R$7.3bn | -R$5.1bn | -R$3.8bn |
| Gross profit | R$1.7bn | R$1.3bn | R$1.7bn | R$1.4bn | R$1.1bn | R$638.5m |
| EBITDA | R$862m | -R$551.9m | R$897.1m | R$539.8m | R$590.5m | R$279.3m |
| EBIT | R$531.7m | -R$863m | R$636.5m | R$513.4m | R$492.3m | R$197m |
| Net finance result | -R$486m | -R$728.6m | -R$498m | -R$305.3m | -R$83.4m | -R$7.4m |
| Profit before tax | R$45.7m | -R$1.6bn | R$138.5m | R$208.1m | R$408.9m | R$189.6m |
| Income tax | -R$27.4m | R$176.1m | R$221.4m | R$51.7m | -R$13.7m | -R$67.8m |
| Net income | R$18.2m | -R$1.4bn | R$359.9m | R$259.7m | R$395.2m | R$121.8m |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
VVEO3 against its sector
The same indicators for the company's other shares and the sector's largest stocks.
| Stock | P/E | P/B | Dividend yield (12m) | ROE | Market cap |
|---|---|---|---|---|---|
| VVEO3Cm Hospitalar | 4.37 | 0.14 | 0.00% | 3.12% | R$251.8m |
| BEEF3MINERVA S.A. | 8.60 | 2.50 | 4.97% | 29.04% | R$3.9bn |
| RIAA3RIAA3 | 2.35 | 0.67 | 46.23% | 28.35% | R$3.6bn |
| PFRM3PROFARMA DISTRIB PROD FARMACEUTICOS S.A. | 5.94 | 0.64 | 8.70% | 10.71% | R$917.5m |
| WLMM4WLM PART. E COMÉRCIO DE MÁQUINAS E VEÍCULOS S.A. | 7.37 | 0.71 | 12.38% | 9.63% | R$590.4m |
| WLMM3WLM PART. E COMÉRCIO DE MÁQUINAS E VEÍCULOS S.A. | 7.74 | 0.75 | 10.71% | 9.63% | R$590.4m |
| DMVF3D1000 VAREJO FARMA PARTICIPAÇÕES S.A. | 14.08 | 0.33 | 0.00% | 2.35% | R$306.1m |
Does VVEO3 pay dividends?
Dividend yield per year
- 2.53%2022
- 1.98%2023
- 6.66%2024
- 0.00%2025
- 0.00%2026
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Dividend | 30/04/2024 | 19/12/2024 | R$0.14 |
| Interest on equity | 26/12/2022 | 16/02/2023 | R$0.28 |
| Dividend | 29/04/2022 | 11/05/2022 | R$0.16 |
| Interest on equity | 28/12/2021 | 23/02/2022 | R$0.25 |
About Cm Hospitalar
- Sector
- Consumo Não Cíclico
- Segment
- Medicamentos e Outros Produtos
- Listing segment
- Novo Mercado
- Tag along
- 100.00%
- Free float
- 60.23%
- Shares issued
- 322.82m ordinary
- Average daily trading
- R$758.9k
- Listed since
- 09/08/2021
- CNPJ
- 12.420.164/0001-57
Viveo S.A. é uma empresa brasileira atuante no segmento de saúde e bem-estar, especializada em serviços de saúde, diagnóstico e produtos de bem-estar. A companhia opera em segmentos de serviços de saúde, diagnóstico por imagem e comercialização de produtos de bem-estar, atendendo mercados doméstico. Viveo está envolvida em atividades de prestação de serviços de saúde e distribuição de produtos de bem-estar. A companhia é um player importante no segmento de saúde e bem-estar do Brasil, operando com foco em qualidade de seus serviços. Com receita anual superior a R$ 200 milhões, a Viveo é um importante prestador de serviços de saúde do Brasil. A empresa está comprometida com qualidade de seus serviços, inovação em diagnóstico e bem-estar de seus clientes.
Investor website| Shareholder | Ordinary | Preferred | Total |
|---|---|---|---|
| Genoma VI Fundo de Investimento em Participações MultiestratégiaControlling | 21.61% | 0.00% | 21.61% |
| FUNDO DE INVESTIMENTOS EM PARTICIPAÇÕES MULTIESTRATÉGIA GENOMA IControlling | 15.58% | 0.00% | 15.58% |
| PEREA CAPITAL PARTNERS, LP | 15.02% | 0.00% | 15.02% |
| DARWIN FUNDO DE INVESTIMENTO MULTIMERCADO - CREDITO PRIVADO INVESTIMENTO NO EXTERIORControlling | 0.12% | 0.00% | 0.12% |
| DIAMANTINA FIC DE FIM CP IEControlling | 0.06% | 0.00% | 0.06% |
| LUIZ FELIPE DUARTE MARTINS COSTAControlling | 0.06% | 0.00% | 0.06% |
| JOSÉ EDUARDO RIBEIRO GUINLEControlling | 0.05% | 0.00% | 0.05% |
| DINA FIM CP IEControlling | 0.04% | 0.00% | 0.04% |
| DNA CAPITAL CONSULTORIA LTDAControlling | 0.01% | 0.00% | 0.01% |
| Outros | 45.31% | 0.00% | 45.31% |
| Ações Tesouraria | 2.13% | 0.00% | 2.13% |
Questions about VVEO3
How much is VVEO3 today?
VVEO3 is at R$0.77 (-2.53% on the day), last traded on 01/10/2026.
How much did VVEO3 pay in dividends in 2025?
VVEO3 paid R$0.00 per share in 2025, a dividend yield of 0.00%.
What are the P/E and P/B of VVEO3?
VVEO3 trades at a P/E of 4.37 and a P/B of 0.14.
How much did VVEO3 return in 12 months?
VVEO3 returned -45.83% in 12 months, with annualised volatility of 61.46% and a largest drawdown of -60.00%.
What sector is VVEO3 in?
Cm Hospitalar is in the Consumo Não Cíclico sector, Medicamentos e Outros Produtos segment.